This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Living Cell Technologies, Ltd.
Drug Names(s): Immunoprotected (alginate encapsulated) porcine choroid plexus cells for xenotransplantation
Description: NTCELL is a choroid plexus cell product that helps cells produce cerebrospinal fluid as well as a range of neurotrophins.
LCT and Otsuka
In December 2012, Living Cell Technologies (LTC) announced the signing of an agreement with Otsuka to co-develop NTCELL for the treatment of Parkinsons disease and other neurological disorders.
LCT will receive an upfront payment of $3m within 30 days of signing. In addition, Otsuka will fund all development costs, estimated at $2m, to complete the previously announced Phase I trial of NTCELL in Parkinsons disease. LCT will receive a further milestone payment of $2m when the first patient in the Phase I Parkinsons trial has been safely implanted with NTCELL. In return, LCT has granted Otsuka an exclusive option to jointly develop and commercialise NTCELL in Parkinsons and other neurological diseases, including hearing loss, through Diatranz Otsuka, the 50:50 joint venture formed between LCT and Otsuka. If Otsuka exercises this option it will subscribe for $20 million of additional equity into DOL to fund the ongoing development of NTCELL in Parkinsons...See full deal structure in Biomedtracker
Partners: Otsuka Holdings Co., Ltd.
Additional information available to subscribers only: